Göteborg, Sweden, 2014-04-15 10:33 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) (”Immunicum”) has decided to change the date of publication of its interim report for the period 1 July 2013 – 31 March 2014. The new date of publication is 7 May 2014. The previously announced date of publication was 20 May 2014.
The reason for bringing forward the date of publication is that Immunicum wants to publish the interim report well in advance of the subscription period in the forthcoming rights issue.
For further information please contact:
Jamal El-Mosleh, CEO of Immunicum, +46 31 41 50 53,
About Immunicum AB (publ):
Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Since the raw material consists of allogeneic dendritic cells, Immunicum’s products can be produced in large scale. The vaccines are now undergoing clinical trials in renal cell carcinoma and hepatocellular carcinoma.
Redeye AB is chosen as Immunicum’s Certified Adviser.
Tel: 08-545 013 31. www.redeye.se